TOP TIERMARKET NEWSWIRE

News & sentiment

ENLIVEN THERAPEUTICS (ELVN) — News & AI sentiment

ENLIVEN THERAPEUTICS (ELVN) news roundup. 11 stories aggregated over the last 30 days. Average 30-day sentiment is 61.5/100. Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 8 sales totalling $11.8M — net selling of $11.8M. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

0

30d stories

11

avg sentiment 61.5/100

Insider net (90d)

$11.8M

0 buys · 8 sells

Congress (90d)

0

0 buys · 0 sells

ELVN news in the last 24 hours, 7 days, 30 days and 90 days

How much ELVN coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	ELVN stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	0	—	no coverage
Last 30 days	11	61.5/100	ELVN headlines →
Last 90 days	26	59.1/100	ELVN headlines →

Latest stories on ELVN

H.C. Wainwright raises Enliven Therapeutics price target to $73

Investing.com Analyst Ratings64 · neutralanalyst

Oct 19

Enliven Therapeutics, Inc. (ELVN) files 8-K

SEC 8-K50 · neutralgeneral

Oct 14

Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year

PR Newswire58 · neutralproduct/pr

Oct 14

Guggenheim reiterates Enliven Therapeutics stock rating on FDA alignment

Investing.com Analyst Ratings52 · neutralanalyst

Oct 8

ELVN Gains a Clear FDA Path for a 450-Patient Phase 3 Relcobatinib Study in Previously Treated CML October 7, 2026

MarketChameleon73 · bullishproduct/pr

Oct 7

Enliven, FDA agree on phase 3 trial design for relcobatinib for chronic myeloid leukemia

Seeking Alpha67 · bullishproduct/pr

Oct 7

Enliven reaches alignment with FDA on final design of ENABLE-2 pivotal trial

The Fly63 · neutralgeneral

Oct 6

Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia

PR Newswire67 · bullishproduct/pr

Oct 6

Enliven initiated with an Overweight at Morgan Stanley

The Fly61 · neutralanalyst

Oct 2

Morgan Stanley initiates Enliven Therapeutics stock at overweight

Investing.com Analyst Ratings61 · neutralanalyst

Oct 2

Enliven Therapeutics stock initiated at Overweight by JPMorgan

Investing.com Analyst Ratings61 · neutralanalyst

Oct 1

Enliven Therapeutics, Inc. (ELVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha56 · neutralgeneral

Sep 16

Enliven Therapeutics to Present at Upcoming Investor Conferences

PR Newswire56 · neutralgeneral

Sep 3

Enliven Therapeutics: A Clean Active-Site TKI Could Redefine CML Sequencing

Seeking Alpha63 · neutralproduct/pr

Sep 3

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

PR Newswire56 · neutralproduct/pr

Aug 31

Enliven a new outperform at Barclays on potential of CML asset

Seeking Alpha67 · bullishanalyst

Aug 18

Enliven price target raised to $73 from $62 at Mizuho

The Fly67 · bullishanalyst

Aug 18

William Blair initiates Enliven Therapeutics stock with outperform rating

Investing.com Analyst Ratings61 · neutralanalyst

Aug 18

Barclays initiates Enliven Therapeutics stock at Overweight, $78 PT

Investing.com Analyst Ratings61 · neutralanalyst

Aug 18

Enliven initiated with an Outperform at William Blair

The Fly61 · neutralanalyst

Aug 18

Enliven initiated with an Overweight at Barclays

The Fly61 · neutralanalyst

Aug 18

Enliven price target raised to $75 from $60 at Baird

The Fly65 · bullishanalyst

Aug 6

Guggenheim lowers Enliven Therapeutics stock price target to $78

Investing.com Analyst Ratings34 · bearishanalyst

Aug 6

Enliven Therapeutics GAAP EPS of -$0.49 misses by $0.10

Seeking Alpha34 · bearishearnings

Aug 5

Enliven Therapeutics, Inc. (ELVN) files 8-K

SEC 8-K50 · neutralgeneral

Aug 5

Open ELVN in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →